This was the first study to demonstrate that the frequency of circulating CD4+CD25+CD127loFoxP3+ Treg cells has potential as a dynamic marker for distinguishing pseudoprogression from hyperprogression and for predicting the response to ICI treatment in advanced NSCLC patients. The gene discussed is CD4; the disease is non-small cell lung carcinoma.